NewLink Genetics Corp. (Nasdaq: NLNK) reported updated data from an ongoing Phase 2NLG2103 study of indoximod in combination with KEYTRUDA sending the stock price soaring $4.07 to close at $17.67.
NewLink Genetics reports updated data
September 08, 2017 at 19:17 PM EDT
